Skip to main content
OpenTrials

Clinical trial condition

Endometrial Mixed Cell Adenocarcinoma

Explore clinical trials studying Endometrial Mixed Cell Adenocarcinoma. Study availability and eligibility vary by location and protocol.

9 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Endometrial Mixed Cell Adenocarcinoma trial results

Recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

NCT05256225

Conditions
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +17 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
View all 409 locations
View Trial Details
Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

NCT05112601

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University Cancer and Blood Center LLC Athens, Georgia, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • Saint Alphonsus Cancer Care Center-Boise Boise, Idaho, United States
View all 137 locations
View Trial Details
Completed

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

NCT01935934

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
View all 19 locations
View Trial Details
Completed

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02020707

Conditions
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, +45 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details
Completed

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT02728258

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +24 more
Locations
  • Yale University New Haven, Connecticut, United States
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
  • University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States
  • Northside Hospital Atlanta, Georgia, United States
View all 43 locations
View Trial Details
Completed

Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01935973

Conditions
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, +3 more
Locations
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View all 22 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

NCT03914612

Conditions
Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +30 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas, United States
View all 397 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

NCT03660826

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +28 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 762 locations
View Trial Details

Related conditions